成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Cell Cycle/DNA Damage Stem Cell/Wnt JAK/STAT Signaling Apoptosis
  3. Nucleoside Antimetabolite/Analog DNA/RNA Synthesis STAT Apoptosis
  4. Fludarabine

Fludarabine  (Synonyms: 氟達(dá)拉濱; F-ara-A; NSC 118218)

目錄號(hào): HY-B0069 純度: 99.91%
COA 產(chǎn)品使用指南 技術(shù)支持

Fludarabine (F-ara-A; NSC 118218) 是一種 DNA 合成抑制劑和一種在淋巴增生性惡性腫瘤中具有抗腫瘤活性的氟化嘌呤類似物。Fludarabine 抑制細(xì)胞因子誘導(dǎo)的正常靜止或激活淋巴細(xì)胞中 STAT1 和 STAT1 依賴性基因轉(zhuǎn)錄的激活。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Fludarabine Chemical Structure

Fludarabine Chemical Structure

CAS No. : 21679-14-1

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥550
In-stock
5 mg ￥496
In-stock
10 mg ￥750
In-stock
25 mg ￥1428
In-stock
50 mg ￥2285
In-stock
100 mg ￥3199
In-stock
200 mg   詢價(jià)  
500 mg   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Fludarabine:

MCE 顧客使用本產(chǎn)品發(fā)表的 61 篇科研文獻(xiàn)

WB

    Fludarabine purchased from MCE. Usage Cited in: Nat Commun. 2021 Mar 29;12(1):1940.  [Abstract]

    SW1990 cells transfected with indicated 20, 50 μM Fludara with 20 ng/mL IFN-γ for 24 hours, immunoblotting analyses are performed using the indicated antibodies.

    Fludarabine purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2019 Aug 22;38(1):370.  [Abstract]

    Western blot of JAK2 and STAT1 phosphorylation and CXCL1 expression in cells pretreated with Fludarabine (100?μM) for 1?h and subsequently treated with VP-16 (20?μM) or CPT-11 (80?μg/mL) for 0.5?h.

    查看 STAT 亞型特異性產(chǎn)品:

    • 生物活性

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes[1][2][3][4].

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    47.44 μM
    Compound: fludarabine
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 20605656]
    CCRF-CEM IC50
    19.49 μM
    Compound: fludarabine
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    		[PMID: 20605656]
    HCT-116 IC50
    6.6 μM
    Compound: Fludarabine
    Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
    Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
    		[PMID: 25462277]
    HCT-116 IC50
    8 μM
    Compound: Fludarabine
    Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay
    		[PMID: 29326016]
    HeLa EC50
    16 μM
    Compound: Flu
    Antitumor activity against human HeLa cells assessed as cell viability by MTT assay
    Antitumor activity against human HeLa cells assessed as cell viability by MTT assay
    		[PMID: 24673739]
    HepG2 IC50
    20 μM
    Compound: Fludarabine
    Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay
    		[PMID: 29326016]
    Huh-7 IC50
    30 μM
    Compound: Fludarabine
    Antiproliferative activity against human HuH7 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HuH7 cells after 72 hrs by SRB assay
    		[PMID: 29326016]
    Huh-7 IC50
    60.1 μM
    Compound: Fludarabine
    Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay
    Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay
    		[PMID: 25462277]
    JVM-2 EC50
    10.4 μM
    Compound: Flu
    Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis
    Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis
    		[PMID: 24673739]
    K562 IC50
    0.26 μM
    Compound: fludarabine
    Cytotoxicity against human paclitaxel-resistant K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human paclitaxel-resistant K562 cells after 72 hrs by MTT assay
    		[PMID: 20605656]
    K562 IC50
    0.6 μg/mL
    Compound: Fludarabine
    Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay
    Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay
    		[PMID: 12617912]
    K562 IC50
    0.6 μg/mL
    Compound: Fludarabine
    Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay
    Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay
    		[PMID: 12617912]
    K562 IC50
    267 μM
    Compound: fludarabine
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 20605656]
    Mahlavu IC50
    10 μM
    Compound: Fludarabine
    Antiproliferative activity against human Mahlavu cells after 72 hrs by SRB assay
    Antiproliferative activity against human Mahlavu cells after 72 hrs by SRB assay
    		[PMID: 29326016]
    MCF7 IC50
    15 μM
    Compound: Fludarabine
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 29326016]
    PBMC IC50
    1.9 μM
    Compound: fludarabine
    Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay
    Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay
    		[PMID: 25562417]
    PBMC IC50
    10 μM
    Compound: fludarabine
    Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay in presenc of mouse M210B4 cells
    Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay in presenc of mouse M210B4 cells
    		[PMID: 25562417]
    PBMC IC50
    14 μM
    Compound: fludarabine
    Cytotoxicity against healthy human PBMC after 48 hrs by CellTitre-Blue assay
    Cytotoxicity against healthy human PBMC after 48 hrs by CellTitre-Blue assay
    		[PMID: 25562417]
    T47D IC50
    46.2 μM
    Compound: Fludarabine
    Cytotoxicity against human T47D cells after 72 hrs by SRB assay
    Cytotoxicity against human T47D cells after 72 hrs by SRB assay
    		[PMID: 25462277]
    體外研究
    (In Vitro)

    Fludarabine（5 μM；48 小時(shí)）誘導(dǎo) p27kip1 表達(dá)降低[4]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[4]

    Cell Line: B-CLL cells
    Concentration: 5 μM
    Incubation Time: 24 hours
    Result: Induces a decrease in p27kip1 expression. The decrease in p27kip1 expression was significantly correlated to the extent of in vitro apoptosis.
    體內(nèi)研究
    (In Vivo)

    Fludarabine（0.8 mg/kg；腹腔注射；兩個(gè)周期，每 2 周 1 次，每次 5 天）與 Cyclophosphamide（400 mg/kg；腹腔注射；2 周）聯(lián)合使用可降低 GVHD 的發(fā)生率[6]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: F-1 mice received 105 BCL-1 leukemia cells[6]
    Dosage: 0.8?mg/kg
    Administration: Intraperitoneal injection; two cycles for 5 days every 2 weeks
    Result: Combination with Cyclophosphamide decreased incidence of graft-versus-host disease (GVHD).
    Clinical Trial
    分子量

    285.24

    Formula

    C10H12FN5O4
    CAS 號(hào)
    性狀

    固體

    顏色

    White to yellow

    中文名稱

    磷酸氟達(dá)拉濱EP雜質(zhì)E)
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲(chǔ)存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : 25 mg/mL (87.65 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 3.5059 mL 17.5294 mL 35.0588 mL
    5 mM 0.7012 mL 3.5059 mL 7.0118 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn)：

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (8.76 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請(qǐng)依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (8.76 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

    以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶。

    • 方案 一

      請(qǐng)依序添加每種溶劑： 50% PEG300    50% Saline

      Solubility: 5 mg/mL (17.53 mM); 懸濁液; 超聲助溶

    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    只
    由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.91%

    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.5059 mL 17.5294 mL 35.0588 mL 87.6470 mL
    5 mM 0.7012 mL 3.5059 mL 7.0118 mL 17.5294 mL
    10 mM 0.3506 mL 1.7529 mL 3.5059 mL 8.7647 mL
    15 mM 0.2337 mL 1.1686 mL 2.3373 mL 5.8431 mL
    20 mM 0.1753 mL 0.8765 mL 1.7529 mL 4.3824 mL
    25 mM 0.1402 mL 0.7012 mL 1.4024 mL 3.5059 mL
    30 mM 0.1169 mL 0.5843 mL 1.1686 mL 2.9216 mL
    40 mM 0.0876 mL 0.4382 mL 0.8765 mL 2.1912 mL
    50 mM 0.0701 mL 0.3506 mL 0.7012 mL 1.7529 mL
    60 mM 0.0584 mL 0.2922 mL 0.5843 mL 1.4608 mL
    80 mM 0.0438 mL 0.2191 mL 0.4382 mL 1.0956 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Fludarabine
    目錄號(hào)：
    HY-B0069
    需求量：